Stock Pick

Buy, hold, sell: New Hope, REA, Telix Pharmaceuticals shares

Written by

openjargon

in

Couple using their digital tablet together.

S&P/ASX 200 Index (ASX: XJO) shares are down 0.9% to 8,689.1 points on Thursday.

Meanwhile, three experts share their views on three ASX 200 shares.

Let’s take a look.

Telix Pharmaceuticals Ltd (ASX: TLX)

The Telix Pharmaceuticals share price is $16.02, down 0.4% today and up 4% over 12 months. 

Bell Potter has a buy rating on this ASX 200 healthcare share. 

Analyst John Hester said: 

TLX has announced a scrip-based merger with the privately owned ITM Group, based in Germany for consideration of up to US$2.35bn.

ITM is a leading manufacturer of therapeutic isotopes, including Lu-177, being the dominant therapeutic isotope for the treatment of cancers including for the Novartis blockbuster Pluvicto.

The merger creates a vertically integrated radiopharmaceutical company with enhanced capabilities across development, isotope production and global manufacturing.

[The merger] represents a once in a lifetime opportunity to acquire a dominant share in the supply of Lu-177 that is very difficult to replicate. While earnings may take a year or two to realise, the underlying value is obvious.

New Hope Corporation Ltd (ASX: NHC)

The New Hope Corporation share price is $5.86, down 0.09% today and up 49% over 12 months. 

Morgans has a hold rating on this ASX 200 coal share.

The broker said: 

Cash surprise drives dividend beat – Strong operational delivery and a year-end cash balance of A$485m supported a fully franked 30cps final dividend, materially ahead of MorgansF (20cps) and consensus (14cps).

Operational performance exceeded expectations – NHC delivered record saleable coal production of 11.5Mt and coal sales of 11.8Mt, exceeding the top end of guidance and demonstrating the resilience of its operations despite disruptions throughout the year.

Strong run, balanced view – NHC shares have rallied 60% YTD, supported by stronger coal prices and improving market sentiment. While we remain constructive on thermal coal fundamentals, the recent share price performance may provide an opportunity for investors to crystallise some gains.

REA Group Ltd (ASX: REA)

The REA share price is $151.55, down 0.5% today and down 34% over 12 months. 

Morgans has a sell rating on this ASX 200 communications share. 

Analyst Michael Ardrey said:

Despite REA’s ability to generate strong results in challenged operating environments, we continue to see significant downside risk to listings volumes/earnings vs. company guidance and consensus and await further data points via lending volumes and market listings before re-considering our thesis.

The post Buy, hold, sell: New Hope, REA, Telix Pharmaceuticals shares appeared first on The Motley Fool Australia.

Should you invest $1,000 in Telix Pharmaceuticals right now?

Before you buy Telix Pharmaceuticals shares, consider this:

Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Telix Pharmaceuticals wasn’t one of them.

The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

And right now, Scott thinks there are 5 stocks that may be better buys…

See the 5 Stocks

* Returns as of 1 August 2026

.custom-cta-button p {
margin-bottom: 0 !important;
}

More reading

Motley Fool contributor Bronwyn Allen has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Telix Pharmaceuticals. The Motley Fool Australia has recommended Telix Pharmaceuticals. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More posts